Elsevier

European Urology

Volume 69, Issue 5, May 2016, Pages 841-843
European Urology

Platinum Priority – Editorial
Referring to the article published on pp. 834–840 of this issue
The Ongoing Challenges of Targeting the Androgen Receptor

https://doi.org/10.1016/j.eururo.2015.10.052Get rights and content

Section snippets

Conflicts of interest

Johann de Bono is employed by the Institute of Cancer Research, which has a commercial interest in abiraterone acetate. He has served as the chief investigator of the registration abiraterone, enzalutamide, and cabazitaxel phase 3 studies and has participated in advisory boards run by Janssen, Astellas, Sanofi, Takeda, and AstraZeneca.

Funding support

The authors are supported by a Cancer Research UK Centre grant, an Experimental Cancer Medicine Center grant, National Institute for Health Research Biomedical Research Center funding, and support from Movember, Prostate Cancer UK, and the Prostate Cancer Foundation.

View full text